Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1634 1671 1678 1682
This examiner grants 49% of resolved cases
Examiner Carla J Myers has resolved 1035 cases in Art Unit 1600. Within Tech Center 1600, the examiner has an allowance rate of 49.3 percent. This 49.3 percent rate is derived from the 1035 cases that have reached a final resolution, providing a benchmark for practitioners.
The median days to allowance is 1136. This 1136 day figure marks the middle point of the duration for successful prosecutions. Applicants should account for this 1136 day timeline when managing expectations for applications assigned to this examiner in Art Unit 1600.
The interview lift is 46.1 percent, which indicates an increase in the probability of allowance when an interview is conducted relative to the 49.3 percent base rate. This 46.1 percent lift suggests that interviews are associated with a higher likelihood of allowance. The 46.1 percent lift provides a statistical basis for engaging in direct communication with the examiner in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18606690 | METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES | Non-Final OA | 10x Genomics, Inc. |
| 18717006 | SINGLE-CELL CULTURE AND SEQUENCING WITH LIPID-MODIFIED OLIGOS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17653114 | Systems and Methods to Identify Pancreatic Ductal Adenocarcinoma and Uses Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18343768 | Structured Nucleic Acid Templated Architectures | Non-Final OA | Massachusetts Institute of Technology |
| 18023249 | TARGET MEASUREMENT METHOD, TARGET MEASUREMENT DEVICE, TARGET MEASUREMENT APPARATUS, AND TARGET MEASUREMENT KIT | Non-Final OA | Yokogawa Electric Corporation |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18264314 | METHODS AND BIOMARKERS IN CANCER | Non-Final OA | New York University |
| 18607269 | METHODS OF TREATING PANCREATIC CANCER | Non-Final OA | University of Washington |
| 18742149 | METHODS FOR DETECTING AND TREATING PROPRANOLOL SENSITIVE TUMORS | Non-Final OA | University of South Florida |
| 18030801 | METHODS AND AGENTS FOR TREATING, PREVENTING, DIAGNOSING, AND EVALUATING THERAPY FOR FIBROTIC, AUTOIMMUNE, AND INFLAMMATORY CONDITIONS | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 18095386 | NON-INVASIVE PRENATAL SAMPLE PREPARATION AND RELATED METHODS AND USES | Final Rejection | Myriad Women's Health, Inc. |
| 18420482 | INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS | Non-Final OA | Illumina, Inc. |
| 17026069 | METHODS AND COMPOSITIONS FOR IDENTIFYING LIGANDS ON ARRAYS USING INDEXES AND BARCODES | Non-Final OA | ILLUMINA, INC. |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17641502 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18021748 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | Final Rejection | BicycleTx Limited |
| 18287245 | PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS | Non-Final OA | NANJING GENSCRIPT BIOTECH CO., LTD. |
| 17918468 | PROGNOSIS METHOD OF ACUTE MYELOID LEUKAEMIA | Non-Final OA | UNIVERSITÉ DE MONTPELLIER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy